Floatz logo

Midostaurin

AML and High Risk MDS

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the AML and High Risk MDS cohort.

Asset / SponsorPhaseRating
PIM KINASE INHIBITOR LGH447
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Midostaurin is also rated in:

acute myeloid leukemia by FAB classificationDormant
B
Indicative ·
63 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →